Free Trial
ASX:RCE

Recce Pharmaceuticals (RCE) Stock Price, News & Analysis

Recce Pharmaceuticals logo

About Recce Pharmaceuticals Stock (ASX:RCE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
630,087 shs
Average Volume
N/A
Market Capitalization
A$104.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCE Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

RCE Stock Analysis - Frequently Asked Questions

Recce Pharmaceuticals Ltd (ASX:RCE) issued its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.01) earnings per share for the quarter. Recce Pharmaceuticals had a positive trailing twelve-month return on equity of 392.94% and a negative net margin of 741.65%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Prima BioMed (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS).

Company Calendar

Last Earnings
2/27/2019
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:RCE
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$17.66 million
Net Margins
-741.65%
Pretax Margin
N/A
Return on Equity
392.94%
Return on Assets
-238.11%

Debt

Debt-to-Equity Ratio
-8.52
Current Ratio
0.34
Quick Ratio
4.81

Sales & Book Value

Annual Sales
A$5.03 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
13.57
Book Value
A($0.05) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
231,870,000
Free Float
N/A
Market Cap
A$104.34 million
Optionable
Not Optionable
Beta
1.05
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (ASX:RCE) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners